<DOC>
	<DOCNO>NCT00905450</DOCNO>
	<brief_summary>This clinical study conduct identify effective drug concentration dose frequency BOL-303242-X ( Mapracorat ) ophthalmic suspension , treatment inflammation follow cataract surgery .</brief_summary>
	<brief_title>Evaluation BOL-303242-X Versus Vehicle Treatment Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<criteria>Subjects must least 18 year age date Informed Consent Form ( ICF ) sign capacity voluntarily provide consent . Subjects must able understand provide write consent Institutional Review Board ( IRB ) /Ethics Committee ( EC ) approve ICF provide authorization appropriate local privacy regulation . Subjects candidate cataract surgery . Subjects childbearing potential female subject negative urine pregnancy test result screen . Subjects must able willing comply treatment follow procedure . Subjects know hypersensitivity contraindication study drug ( ) component . Subjects history presence chronic generalize systemic disease Investigator feel might increase risk subject confound result study . Subjects severe/serious ocular condition , unstable medical condition , Investigator 's opinion , may preclude study treatment followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Surgery</keyword>
</DOC>